Introduction
The genetic toxicity database ofthe U.S. National Toxicology Program (NTP) has evolved over approximately a 10-year period. The database was an indirect product ofefforts to develop and evaluate methods to detect mutagens and identify potential carcinogens. The latter goal was predominant because the duration and cost of identifying carcinogens through animal bioassays mandates that other methods be sought to reduce dependence on the bioassay.
The efforts of other organizations such as the International Program for Chemical Safety (IPCS) and the U.S. Environmental Protection Agency (EPA) to conduct their own evaluations of methods to identify carcinogens led to the realization that a concerted effort to develop in vitro genetic toxicity data was mandatory if an evaluation was ultimately to have any influence on the use of in vitro or in vivo short-term tests (STTs) . Results emerging from the IPCS and EPA studies indicated the necessity of developing assay protocols that could yield at least qualitatively reproducible results within and between laboratories. This goal was generallly achieved by the NTP by having two or more laboratories test identical chemicals that were submitted under code. The use of fixed protocols and coded chemicals, however, create the disadvantage that assays cannot be adapted to pH, etc. However, the objective value ofthe data obtained by the assay of coded chemicals was judged to outweigh the other limitations. The principal source oferror introduced by the use of coded chemicals is that while a positive response may be definitive, a negative response might be conditional and could be changed by a more appropriate assay protocol. However, since most ofthe assays evaluated by the NTP were subjected to coded chemicals, it may be assumed that there was a consistent bias for all of the STTs.
Another result of the IPCS and EPA studies was the demonstration that too few of the chemicals had been tested in all systems and that there was an inadequate number of noncarcinogens tested in any STT. In this regard, the NTP rodent bioassay database provided the most appropriate source of chemicals to meet these deficiencies. Some specific aspects of the data need to be emphasized in relationship to the genetic toxicity database.
Over the past two decades, the rodent carcinogenicity studies conducted by the National Institutes ofHealth have been generally consistent in regard to the assay protocols, strains of rodents, characterization of chemicals, and the use of a biologically active dose, the so-called maximum The combined data sets were evaluated for the standard parameters of assay performance (sensitivity and specificity) and the Salmonella assay which had the lowest sensitivity (0.48), demonstrated the highest specificity (0.91). Conversely, the mouse lymphoma mutagenesis assay had the highest sensitivity (0.72) but the lowest specificity (0.40). The overall concordance (accuracy) ofthe four assays were 0.66, 0.61, 0.59, and 0.59 for Salmonella, chromosome aberrations, SCE, and mouse lymphoma cells, respectively. For these chemicals, Salmonella mutagenesis had the best predictive value for carcinogenicity (89 %), but a negative response in any of these assays was not predictive for noncarcinogens. It is important to note that there was no complementarity among these four in vitro assays and that no combination ofthese four assays was more predictive of carcinogenic potential than the Salmonella assay alone. Table 2 . It is to be emphasized that these noncarcinogens are operationally identified on the basis ofexposure of two rodent species for up to 104 weeks to an MTD. Many of these substances are relatively nontoxic and were thus administered to the animals at relatively high doses. This is the most extensive list available ofoperationally defined noncarcinogens that lack structural alerts for mutagenicity.
There is one other important component ofthe NTP database that can be ofgreat value in validating any new assays purported to identify carcinogens. There are currently about 50 substances that are in some phase of the rodent bioassay. These phases range from ongoing subchronic (i.e., 90 day) toxicity assays for establishing an MTD level for the 2-year assays, to the 2-year studies nearing completion. The carcinogenic potential for these agents is not now known, but it will be established within a 2-to 3-year period. Forty-four of these substances have been used recently to prospectively evaluate the predictive potential of structural alerts and Salmonella mutagenicity for identifying carcinogens (44) . In addition, because nonmutagenic substances are also included in this group, it was also an opportunity to evaluate the predictive value of subchronic organ-specific toxicity. These same chemicals have been used in two other prediction exercises with computer-based expert systems (43) . These substances under test represent a unique database that can be used to significantly shorten the time and effort required to evaluate and validate other methods of characterizing potential carcinogens.
Discussion
It must be emphasized that the genetic toxicity database ofthe NTP will only continue to enlarge in specific areas. Limited numbers of new chemicals are being tested for mutagenicity in Salmonella and for chromosomal aberrations in vitro and in vivo. The concept of identifying one or a few in vitro short-term tests with which to screen large numbers of chemicals and to specifically identify potential carcinogens has not been supported by the studies cited above. The NTP attempts to use structural information, Salmonella mutagenicity, in vio cytogenetic effects, and selected subchronic toxicity results as risk factors for potential carcinogens. There is also a continuing effbrt to develop There is one other important issue related to the development of databases. An important factor in the conclusions that have been reached about the relationship between in vitro short-term tests and rodent carcinogenicity studies has been the availability of data on rodent noncarcinogens. An equally important factor in efforts to understand the extended relationships between these rodent or in vitro data and the risk of induced carcinogenesis in humans is the absence ofa database on substances that are probably not carcinogenic to humans. Without the ability to determine the effects of such substances in assays that are supposed to detect carcinogenic potential, there will continue to be uncertainty and controversy about weak and equivocal effects of chemicals. If nothing can be judged to be probably noncarcinogenic for humans, then there will continue to be controversy about weakly positive substances identified as carcinogens.
